What is HEPHAISTOS-Pharma?
HEPHAISTOS-Pharma is a preclinical stage Biotech company headquartered in Orsay, Ile-de-France, France. The company is dedicated to developing next-generation oncology treatments designed to boost the immune system and combat incurable cancers. Their innovative approach aims to create therapeutic solutions for some of the most challenging forms of the disease.
How much funding has HEPHAISTOS-Pharma raised?
HEPHAISTOS-Pharma has raised a total of $13.1M across 1 funding round:
Angel/Seed
$13.1M
Angel/Seed (2024): $13.1M with participation from Fournier-Majoie Foundation, Bpifrance, European Investment Centre, and Noshaq
Key Investors in HEPHAISTOS-Pharma
Fournier-Majoie Foundation
The Fournier-Majoie Foundation is dedicated to combating cancer through venture philanthropy, supporting promising oncology research projects and empowering entrepreneurs with innovative therapeutic solutions.
Bpifrance
Bpifrance, a French public investment bank, finances companies at every stage of development, supporting innovation, international expansion, and export activities for startups, SMEs, and mid-cap companies.
European Investment Centre
The European Investment Centre, o.c.p., a.s. is a Slovakian financial institution providing an investment fund platform for advisors and firms, offering infrastructure for managing client accounts and distributing funds across borders.
What's next for HEPHAISTOS-Pharma?
The substantial enterprise-level funding, particularly the recent strategic investment, positions HEPHAISTOS-Pharma for accelerated growth and development. This capital infusion is expected to fuel further research and clinical trials, advancing their pipeline of immune-boosting oncology treatments. The company's focus on incurable cancers suggests a long-term vision for significant impact in the pharmaceutical industry, potentially leading to new therapeutic standards.
See full HEPHAISTOS-Pharma company page
